Fig. 3: Deficient CEACAM6 expression and ERK1/2 signaling in EGFR-TKI resistant lung cancer cells. | npj Precision Oncology

Fig. 3: Deficient CEACAM6 expression and ERK1/2 signaling in EGFR-TKI resistant lung cancer cells.

From: Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma

Fig. 3

A Clonogenic analysis depicting the growth of HCC827 and HCC827GR cells in the presence of increasing concentrations of gefitinib for 14 days. HCC827GR cells were derived from a pool of HCC827 cells that survived incremental concentrations of gefitinib selection over 6 months. B Immunoblotting analysis assessing p-ERK1/2 and p-AKT expression in HCC827 versus HCC827GR cells. p-ERK1/2 and p-AKT expression were quantified using ImageJ software and normalized with GAPDH. C qRT-PCR analysis of CEACAM6 expression in HCC827 versus HCC827GR cells, represented as the cycle-threshold (Ct) values (left) and relative expression folds (right). ***P < 0.001. D ELISA measuring CEACAM5 and CEACAM6 expression in the conditioned medium from HCC827 and HCC827GR cells. E Immunoblotting analysis of CEACAM6 expression in HCC827 versus HCC827GR cells. F GSEA from RNA-seq data identifying differential gene expressions involved in epithelial cell proliferation (left) and ERK1/2 cascade (right) pathways between HCC827 and HCC827GR cells.

Back to article page